In accordance with our Development and Supply Agreement of September 1991, Paragraph 3.1 as well as our letter agreement of July 27, 1992, Matritech and Yamanouchi hereby agree to extend the estimated completion time for the 1st -- antibody pair until...

 
                                                         EXHIBIT 10.10
                                                         -------------
November 30, 1992


FAX:   000-000 0000-0000

Xx. Xxxxxxx Xxxxx
Diagnostic R&D Department
Clinical Development Division
Yamanouchi Pharmaceutical Co., Ltd.
Xx. 0-0 Xxxxxxx 0-xxxxx Xxxxxxxx-xx
Xxxxx 000, Xxxxx

Dear Xx. Xxxxx:

In accordance with our Development and Supply Agreement of September 1991,
Paragraph 3.1 as well as our letter agreement of July 27, 1992, Matritech and
Yamanouchi hereby agree to extend the estimated completion time for the 1st
                                                                         --
antibody pair until June 30, 1993.  As before, the Estimated Completion Time for
subsequent milestones will be extended at six month intervals beyond the 1st
                                                                          --
antibody pair.  This includes both those in paragraphs (2) and (3) of Schedule
A, III.

Very sincerely,



Xxxxxxx X. Xxxxx
president & Chief Executive Officer

SDC:bjr(4014)

Agreed  /s/ Xxxxxxx Xxxxx
        -----------------
          Xxxxxxx Xxxxx, Ph.D.
          Director, Diagnostic R&D Department
          Clinical Development Division
          YAMANOUCHI PHARMACEUTICAL CO., LTD.